Tarsier Pharma
Novel Treatments for Autoimmune Inflammatory Ocular Diseases
StartupTarsier Pharma is a Zikhron Ya'akov-based startup in the Health Tech & Life Sciences sector, established in 2016. Novel Treatments for Autoimmune Inflammatory Ocular Diseases . The company has raised a total of $5.65M across 3 funding rounds, currently at the Seed stage. Tarsier Pharma was founded by Daphne Haim-Langford, Ph.D.. Key investors include BIOLIGHT Life Sciences, Sun Pharmaceutical Industries (India), Xenia Venture Capital. The company has 11-50 employees. Core technologies: Biologicals, Molecules.
With $5.65M in total funding, Tarsier Pharma is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageSeed
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQZikhron Ya'akov
- DistrictCenter District
- Last RoundUndisclosed
- BIOLIGHT Life Sciences
- Sun Pharmaceutical Industries (India)
- Xenia Venture Capital
Daphne Haim-Langford, Ph.D.Co-Founder & CEO
13 articles covered by sources including www.prnewswire.com,
www.calcalistech.com,
www.timesofisrael.com,
www.biospace.com,
www.dealstreetasia.com.
What does Tarsier Pharma do?
Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is currently being developed as both eye drops and intravitreal injections. TRS has the potential to effectively control a range of autoimmune and inflammatory ocular diseases as potently as steroids but without the negative side effects. The company's investors include a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. The company has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 879598.
How much funding has Tarsier Pharma raised?
Tarsier Pharma has raised $5.65M in total funding across 3 rounds. The company is currently at the Seed stage. Key investors include BIOLIGHT Life Sciences, Sun Pharmaceutical Industries (India), Xenia Venture Capital.
Who founded Tarsier Pharma?
Tarsier Pharma was founded in 2016 by Daphne Haim-Langford, Ph.D. (Co-Founder & CEO).
What sector is Tarsier Pharma in?
Tarsier Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.
Where is Tarsier Pharma located?
Tarsier Pharma is based in Yahalom 19, Zikhron Ya'akov, Israel, Center District.